Optimal surgical timing after post-infarction ventricular septal rupture.

acute myocardial infarction cardiogenic shock extracorporeal membrane oxygenation mechanical complications ventricular septal rupture

Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
2022
Historique:
received: 09 09 2021
accepted: 24 11 2021
revised: 23 11 2021
pubmed: 18 5 2022
medline: 7 10 2022
entrez: 17 5 2022
Statut: ppublish

Résumé

Ventricular septal rupture (VSR) following acute myocardial infarction (AMI) is a dangerous condition. Surgical VSR closure is the definitive therapy, but there is controversy regarding the surgical timing and the bridging therapy between diagnosis and intervention. The objective of this study is to analyze the ideal time of surgical repair and to establish the contribution of mechanical circulatory support (MCS) devices on the prognosis. We designed an observational, retrospective, multicenter study, selecting all consecutive patients with post-AMI VSR between January 1, 2008 and December 31, 2018, with non-exclusion criteria. The main objective of this study was to analyze the optimal timing for surgical repair of post-AMI VSR. Secondary endpoints were to determine which factors could influence mortality in the patients of the surgical group. A total of 141 patients were included. We identified lower mortality rates with an odds ratio of 0.3 (0.1-0.9) in patients operated on from day 4 compared with the surgical mortality in the first 24 hours after VSR diagnosis. The use of MCS was more frequent in patients treated with surgery, particularly for intra-aortic balloon pump (IABP; 79.6% vs. 37.8%, p < 0.001), but also for veno-arterial extracorporeal membrane oxygenation (VA-ECMO; 18.2% vs. 6.4%, p = 0.134). Total mortality was 91.5% for conservative management and 52.3% with surgical repair (p < 0.001). In our study, we observed that the lowest mortality rates in patients with surgical repair of post-AMI VSR were observed in patients operated on from day 4 after diagnosis of VSR, compared to earlier interventions.

Sections du résumé

BACKGROUND
Ventricular septal rupture (VSR) following acute myocardial infarction (AMI) is a dangerous condition. Surgical VSR closure is the definitive therapy, but there is controversy regarding the surgical timing and the bridging therapy between diagnosis and intervention. The objective of this study is to analyze the ideal time of surgical repair and to establish the contribution of mechanical circulatory support (MCS) devices on the prognosis.
METHODS
We designed an observational, retrospective, multicenter study, selecting all consecutive patients with post-AMI VSR between January 1, 2008 and December 31, 2018, with non-exclusion criteria. The main objective of this study was to analyze the optimal timing for surgical repair of post-AMI VSR. Secondary endpoints were to determine which factors could influence mortality in the patients of the surgical group.
RESULTS
A total of 141 patients were included. We identified lower mortality rates with an odds ratio of 0.3 (0.1-0.9) in patients operated on from day 4 compared with the surgical mortality in the first 24 hours after VSR diagnosis. The use of MCS was more frequent in patients treated with surgery, particularly for intra-aortic balloon pump (IABP; 79.6% vs. 37.8%, p < 0.001), but also for veno-arterial extracorporeal membrane oxygenation (VA-ECMO; 18.2% vs. 6.4%, p = 0.134). Total mortality was 91.5% for conservative management and 52.3% with surgical repair (p < 0.001).
CONCLUSIONS
In our study, we observed that the lowest mortality rates in patients with surgical repair of post-AMI VSR were observed in patients operated on from day 4 after diagnosis of VSR, compared to earlier interventions.

Identifiants

pubmed: 35578757
pii: VM/OJS/J/85794
doi: 10.5603/CJ.a2022.0035
pmc: PMC9550323
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-781

Références

J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1110-6
pubmed: 10985713
Circulation. 2014 Jun 10;129(23):2395-402
pubmed: 24668286
Front Cardiovasc Med. 2021 Jul 07;8:686558
pubmed: 34307500
Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):617-9
pubmed: 27103450
Curr Opin Cardiol. 2014 Jul;29(4):285-92
pubmed: 24848410
J Am Coll Cardiol. 2018 Oct 16;72(16):1972-1980
pubmed: 30309475
BMC Emerg Med. 2018 Jul 4;18(1):20
pubmed: 29973150
Eur J Heart Fail. 2017 May;19 Suppl 2:124-127
pubmed: 28470919
J Saudi Heart Assoc. 2020 Jul 31;32(2):288-294
pubmed: 33154931
Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(2):128-137
pubmed: 30525871
Int J Cardiol. 2017 Mar 15;231:225-227
pubmed: 27776746
Cardiovasc Revasc Med. 2020 Sep;21(9):1097-1098
pubmed: 32654984
J Investig Med. 2015 Oct;63(7):844-55
pubmed: 26295381
Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):757-764
pubmed: 32883644
J Thorac Cardiovasc Surg. 2010 Nov;140(5):1125-32.e2
pubmed: 20708754
Ann Thorac Surg. 2021 Jul;112(1):326-337
pubmed: 33157063
Int J Cardiol. 2016 Mar 1;206:27-36
pubmed: 26773765
Crit Care. 2019 Jul 30;23(1):266
pubmed: 31362770
Crit Care Clin. 2017 Oct;33(4):813-824
pubmed: 28887929
J Am Coll Cardiol. 2018 Aug 28;72(9):959-966
pubmed: 30139440
JACC Cardiovasc Interv. 2019 Sep 23;12(18):1825-1836
pubmed: 31537282
Heart. 2003 Dec;89(12):1462-6
pubmed: 14617565
JAMA. 1995 May 10;273(18):1450-6
pubmed: 7654275
Semin Thromb Hemost. 2018 Feb;44(1):20-29
pubmed: 28898902
Heart Lung. 2021 Mar-Apr;50(2):292-295
pubmed: 33387761
JACC Cardiovasc Interv. 2016 Feb 22;9(4):341-351
pubmed: 26803418
EuroIntervention. 2016 May 17;12(1):94-102
pubmed: 27173869
Nat Rev Nephrol. 2017 Nov;13(11):697-711
pubmed: 28869251
J Card Surg. 2015 Jun;30(6):535-40
pubmed: 25940559
Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):193-6
pubmed: 23143273
Eur Heart J. 2014 Aug 14;35(31):2060-8
pubmed: 24970335
JACC Cardiovasc Interv. 2021 May 24;14(10):1053-1066
pubmed: 34016403
Ann Thorac Surg. 2019 Oct;108(4):1127-1132
pubmed: 31075249

Auteurs

Juan Diego Sánchez Vega (JD)

Department of Cardiology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERCV, Madrid, Spain.

Gonzalo Luis Alonso Salinas (GL)

Department of Cardiology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERCV, Madrid, Spain.
Department of Cardiology, Complejo Hospitalario de Navarra, Pamplona, Spain.

José María Viéitez Florez (JM)

Department of Cardiology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERCV, Madrid, Spain.
Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Albert Ariza Solé (A)

Department of Cardiology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.

Esteban López de Sá (E)

Department of Cardiology, Hospital Universitario La Paz, IDIPAZ, Madrid, Spain.
Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, Spain.

Ricardo Sanz-Ruiz (R)

Department of Cardiology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Virginia Burgos Palacios (V)

Department of Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Sergio Raposeiras Roubin (S)

Department of Cardiology, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.

Susana Gómez Varela (S)

Department of Cardiology, Hospital Universitario de Cruces, Baracaldo, Sapin.

Juan Sanchís Forés (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBERCV, Valencia, Spain.

Lorenzo Silva Melchor (L)

Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Xurxo Martínez-Seara (X)

Department of Cardiology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

Lorena Malagón López (L)

Department of Cardiology, Complejo Hospitalario de Navarra, Pamplona, Spain.

Ana Viana Tejedor (A)

Department of Cardiology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Clínico San Carlos, Madrid, Spain.

Miguel Corbí Pascual (M)

Department of Cardiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

José Luis Zamorano Gómez (JL)

Department of Cardiology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERCV, Madrid, Spain.

Marcelo Sanmartín-Fernández (M)

Department of Cardiology, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERCV, Madrid, Spain. msanfer@me.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH